As IN VIVOwent to press, we received news that the Food & Drug Administration had rejected Novartis AG 's application for approval of tegaserod (Zelnorm), arguably the company's most important new drug and the only important treatment on the near-horizon for irritable bowel syndrome (IBS). The blow is doubly devastating for the company, coming as it does just weeks after Novartis withdrew the drug's marketing application in Europe when the European Medicines Evaluation Agency (EMEA) appeared ready to deny it approval.
Reaction was predictable. Novartis shares have fallen about 10% since the EMEA meeting—the delays will cost the company, if analysts' projections for the drug are correct, a minimum of several...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?